Should I start interferon beta for my multiple sclerosis?

Hello,

Welcome to icliniq.com

I understand your concern.

Your diagnosis of relapsing, remitting multiple sclerosis (RRMS) means that your immune system intermittently attacks the brain and spinal cord, leading to inflammation and demyelination.

The primary goal of treatment is to reduce relapses, slow disability progression, and prevent new MRI (magnetic resonance imaging) lesions while minimising side effects.

Interferon beta and glatiramer acetate are older, well-established therapies with long-term safety data and modest efficacy, reducing relapse rates by about 30 per cent. They are suitable for mild disease but may cause flu-like symptoms, mild liver enzyme elevation, or injection-site reactions.

Ocrelizumab is a high-efficacy therapy given as an intravenous infusion every six months and works by targeting CD20 (cluster of differentiation 20)-positive B cells.

It reduces relapses and new MRI lesions by approximately 70 per cent and can stabilize early disability, though it increases infection risk and requires careful screening and monitoring.

In younger patients with active or aggressive disease, many neurologists now favour early use of high-efficacy therapies. This approach aims to prevent irreversible neurological damage rather than escalating treatment later.

MRI of the brain, with or without the spine, is performed at baseline and repeated at six to 12 months after starting therapy, then annually. This helps detect new lesions and assess treatment effectiveness.

For interferon therapy, blood counts and liver function tests are usually monitored every three to six months. With Ocrelizumab, baseline hepatitis B screening is essential, along with periodic monitoring of blood counts, liver function, and immunoglobulin levels.

Regular clinical follow-up with a neurologist every three to six months is recommended. New symptoms such as visual changes, imbalance, or sensory disturbances should be reported promptly.

Maintaining adequate vitamin D levels (generally above 40 nanograms per millilitre), engaging in regular physical activity, managing stress, and avoiding smoking can improve long-term outcomes. These measures complement disease-modifying therapy and support overall neurological health.

In short, if your MS shows high activity or frequent relapses, Ocrelizumab offers stronger disease control with manageable monitoring requirements.

If the disease is mild and you prefer a lower-risk option, interferon beta remains a reasonable initial choice, with the final decision guided by your preferences and risk tolerance.

I hope this information is helpful. Please feel free to follow up if you have any further questions.

Thank you.